

# Philipp Mahlknecht

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7502062/publications.pdf>

Version: 2024-02-01

103  
papers

5,134  
citations

81743

39  
h-index

98622

67  
g-index

124  
all docs

124  
docs citations

124  
times ranked

5971  
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors associated with impaired quality of life three months after being diagnosed with COVID-19. <i>Quality of Life Research</i> , 2022, 31, 1401-1414.	1.5	18
2	Prodromal Parkinson's disease: hype or hope for disease-modification trials?. <i>Translational Neurodegeneration</i> , 2022, 11, 11.	3.6	21
3	Optimal deep brain stimulation sites and networks for cervical vs. generalized dystonia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114985119.	3.3	26
4	Neurological outcomes 1 year after COVID-19 diagnosis: A prospective longitudinal cohort study. <i>European Journal of Neurology</i> , 2022, 29, 1685-1696.	1.7	57
5	Associations of Gait Disorders and Recurrent Falls in Older People: A Prospective Population-Based Study. <i>Gerontology</i> , 2022, 68, 1139-1144.	1.4	3
6	How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?. <i>Movement Disorders</i> , 2022, 37, 1581-1592.	2.2	29
7	A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson's disease with dementia. <i>Brain Communications</i> , 2022, 4, .	1.5	3
8	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 146-149.	1.1	7
9	Parkinson's disease laterality: a 11C-PE2I PET imaging study. <i>Journal of Neurology</i> , 2021, 268, 582-589.	1.8	3
10	Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eye-Tracking Study. <i>Movement Disorders</i> , 2021, 36, 1246-1250.	2.2	2
11	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 79-85.	1.1	39
12	Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 155-163.	1.1	4
13	Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study. <i>Movement Disorders</i> , 2021, 36, 1464-1466.	2.2	11
14	Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. <i>Brain</i> , 2021, 144, 1118-1126.	3.7	92
15	Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. <i>European Journal of Neurology</i> , 2021, 28, 3348-3359.	1.7	126
16	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 Year Data from the Open-Label BeyoND Study. <i>Movement Disorders</i> , 2021, 36, 2687-2692.	2.2	20
17	Characterization of gait variability in multiple system atrophy and Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 1770-1779.	1.8	18
18	Reply: Pathophysiology of gait disorders induced by bilateral globus pallidus interna stimulation in dystonia. <i>Brain</i> , 2020, 143, e4-e4.	3.7	1

#	ARTICLE	IF	CITATIONS
19	Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 51-54.	1.1	23
20	Has Deep Brain Stimulation Changed the Very Long-Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 782-787.	0.8	11
21	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal <scp>Population-Based</scp> Cohort. <i>Movement Disorders</i> , 2020, 35, 1658-1662.	2.2	11
22	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 57-63.	1.1	18
23	Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease. <i>Neurologic Clinics</i> , 2020, 38, 255-267.	0.8	34
24	No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements. <i>European Radiology</i> , 2020, 30, 2802-2808.	2.3	5
25	New hopes for disease modification in Parkinson's Disease. <i>Neuropharmacology</i> , 2020, 171, 108085.	2.0	25
26	Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. <i>CNS Drugs</i> , 2019, 33, 905-918.	2.7	92
27	Probabilistic mapping of the antidystonic effect of pallidal neurostimulation: a multicentre imaging study. <i>Brain</i> , 2019, 142, 1386-1398.	3.7	105
28	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. <i>Gerontology</i> , 2019, 65, 216-228.	1.4	63
29	Effect of Low versus High Frequency Subthalamic Deep Brain Stimulation on Speech Intelligibility and Verbal Fluency in Parkinson's Disease: A Double-Blind Study. <i>Journal of Parkinson's Disease</i> , 2019, 9, 141-151.	1.5	22
30	Clinical and genetic characteristics of late-onset Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 101-105.	1.1	17
31	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 90-94.	1.1	49
32	Connectivity derived thalamic segmentation in deep brain stimulation for tremor. <i>NeuroImage: Clinical</i> , 2018, 18, 130-142.	1.4	154
33	Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study. <i>Movement Disorders</i> , 2018, 33, 405-413.	2.2	53
34	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 111-117.	0.8	27
35	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 47-55.	1.1	45
36	Parkinsonian signs in patients with cervical dystonia treated with pallidal deep brain stimulation. <i>Brain</i> , 2018, 141, 3023-3034.	3.7	33

#	ARTICLE	IF	CITATIONS
37	Reader response: Olfaction and incident Parkinson disease in US white and black older adults. <i>Neurology</i> , 2018, 90, 940-940.	1.5	5
38	Impact of Subthalamic Deep Brain Stimulation Frequency on Upper Limb Motor Function in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 267-271.	1.5	10
39	Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 619-623.	2.2	129
40	Letter re: Incident parkinsonism in older adults without Parkinson disease. <i>Neurology</i> , 2017, 88, 919-919.	1.5	2
41	IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 102-103.	1.1	18
42	Consistency of "Probable RBD" Diagnosis with the RBD Screening Questionnaire: A Follow-up Study. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 403-405.	0.8	20
43	Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1174-1182.	2.2	52
44	Characterization of patients with longstanding idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2017, 89, 242-248.	1.5	75
45	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 13-20.	1.1	149
46	Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson's disease. <i>NeuroImage</i> , 2017, 158, 332-345.	2.1	197
47	Insulin signalling: new target for Parkinson's treatments?. <i>Lancet, The</i> , 2017, 390, 1628-1630.	6.3	4
48	Causes of failure of pallidal deep brain stimulation in cases with pre-operative diagnosis of isolated dystonia. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 38-48.	1.1	51
49	Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 36-41.	1.1	67
50	Caveats of Neurodegenerative Risk Stratification in Idiopathic REM Sleep Behavior Disorder by Use of the MDS Research for Prodromal Parkinson's Disease. <i>Sleep</i> , 2017, 40, .	0.6	5
51	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	2.2	44
52	Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community. <i>Movement Disorders</i> , 2016, 31, 1405-1408.	2.2	71
53	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. <i>Movement Disorders</i> , 2016, 31, 1577-1581.	2.2	14
54	Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. <i>Movement Disorders</i> , 2016, 31, 1649-1657.	2.2	35

#	ARTICLE	IF	CITATIONS
55	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1408-1413.	2.2	55
56	Utility of Nigral Signal Intensity Changes on MR Images to Differentiate Drug-induced Parkinsonism from Parkinson Disease. <i>Radiology</i> , 2016, 281, 651-652.	3.6	1
57	The Concept of Prodromal Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 681-697.	1.5	195
58	Plasma fasting cholesterol profiles and age at onset in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1974-1975.	2.2	7
59	Probable RBD and association with neurodegenerative disease markers: A population-based study. <i>Movement Disorders</i> , 2015, 30, 1417-1421.	2.2	86
60	Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 976-981.	2.2	32
61	Invasive Treatment Strategies in a Patient with PARK-15 Associated Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 434-435.	0.8	1
62	Therapeutic advances in multiple system atrophy and progressive supranuclear palsy. <i>Movement Disorders</i> , 2015, 30, 1528-1538.	2.2	17
63	Long-Term Follow-up Investigation of Isolated Rapid Eye Movement Sleep Without Atonia Without Rapid Eye Movement Sleep Behavior Disorder: A Pilot Study. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 1273-1279.	1.4	75
64	Deep brain stimulation for movement disorders: update on recent discoveries and outlook on future developments. <i>Journal of Neurology</i> , 2015, 262, 2583-2595.	1.8	34
65	Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. <i>Neurology</i> , 2015, 84, 654-658.	1.5	164
66	Predictors for mild parkinsonian signs: A prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 321-324.	1.1	27
67	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 145-152.	4.9	90
68	Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 589-592.	2.2	22
69	Motoric cognitive risk syndrome: Multicenter incidence study. <i>Neurology</i> , 2015, 85, 388-389.	1.5	7
70	Novel formulations and modes of delivery of levodopa. <i>Movement Disorders</i> , 2015, 30, 114-120.	2.2	76
71	Movement Disorders in Systemic Diseases. <i>Neurologic Clinics</i> , 2015, 33, 269-297.	0.8	13
72	Movement disorders: new insights into disease mechanisms and treatment. <i>Lancet Neurology</i> , The, 2014, 13, 9-11.	4.9	6

#	ARTICLE	IF	CITATIONS
73	Risk factors and prodromal markers and the development of Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 180-187.	1.8	38
74	Multiple system atrophy as emerging template for accelerated drug discovery in $\alpha$ -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 793-799.	1.1	18
75	Update on diffusion MRI in Parkinson's disease and atypical parkinsonism. <i>Journal of the Neurological Sciences</i> , 2013, 332, 21-29.	0.3	46
76	Diagnosis of drug-induced parkinsonism: can transcranial sonography make the difference?. <i>European Journal of Neurology</i> , 2013, 20, 1429-1430.	1.7	3
77	The PRIPS study: screening battery for subjects at risk for Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 102-108.	1.7	113
78	Nonmotor symptoms in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 581-583.	1.4	15
79	Defining premotor Parkinson's disease: a window of opportunity for neuroprotection?. <i>Neurodegenerative Disease Management</i> , 2013, 3, 61-70.	1.2	2
80	Is there a need to redefine Parkinson's disease?. <i>Journal of Neural Transmission</i> , 2013, 120, 9-17.	1.4	11
81	Substantia Nigra Hyperechogenicity as a Marker for Parkinson's Disease: A Population-Based Study. <i>Neurodegenerative Diseases</i> , 2013, 12, 212-218.	0.8	28
82	Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. <i>Brain</i> , 2013, 136, 3028-3037.	3.7	52
83	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 216-219.	2.2	112
84	Prevalence and Burden of Gait Disorders in Elderly Men and Women Aged 60-97 Years: A Population-Based Study. <i>PLoS ONE</i> , 2013, 8, e69627.	1.1	151
85	Emerging therapies for Parkinson's disease. <i>Current Opinion in Neurology</i> , 2012, 25, 448-459.	1.8	51
86	Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 911-914.	1.4	7
87	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. <i>Proteome Science</i> , 2012, 10, 71.	0.7	22
88	Drug safety evaluation of rotigotine. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 503-512.	1.0	17
89	Is transcranial sonography useful to distinguish drug-induced parkinsonism from Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 1194-1196.	2.2	17
90	A follow-up study of substantia nigra echogenicity in healthy adults. <i>Movement Disorders</i> , 2012, 27, 1196-1197.	2.2	17

#	ARTICLE	IF	CITATIONS
91	Investigation of autonomic function in idiopathic REM sleep behavior disorder. <i>Journal of Neurology</i> , 2012, 259, 1056-1061.	1.8	64
92	Pramipexole extended release in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1229-1234.	1.4	6
93	The influence of deep brain stimulation on pain perception in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1367-1368.	2.2	26
94	Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 932.	4.9	146
95	Significance of MRI in Diagnosis and Differential Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 300-318.	0.8	116
96	Mortality in Parkinson's disease, a 20-year follow-up study. <i>Movement Disorders</i> , 2010, 25, 661-662.	2.2	41
97	Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1357-1363.	2.2	159
98	Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 2444-2449.	2.2	74
99	Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2009, 24, 1906-1909.	2.2	91
100	The clinical progression of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S28-S32.	1.1	123
101	When a Parkinson's disease patient starts to hallucinate. <i>Practical Neurology</i> , 2008, 8, 238-241.	0.5	48
102	Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. <i>Lancet Neurology</i> , The, 2007, 6, 513-520.	4.9	359
103	Depression in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 49-55.	1.8	34